Telehealth company Hims & Hers moved to market a compounded, oral version of semaglutide marketed as a weight‑loss pill, drawing immediate pushback from originator drugmakers and regulators. Novo Nordisk and Eli Lilly flagged legal and safety concerns, arguing the product is an unapproved copy and could mislead patients. Industry statements underscored intellectual property and manufacturing gaps between approved biologics and compounded alternatives. FDA leaders signaled rapid enforcement. FDA Commissioner statements and public comments warned against mass‑marketing of unapproved copycat GLP‑1 products and stressed patient safety risks tied to compounding biologics outside approved manufacturing channels. The episode ramps up legal and regulatory scrutiny at the intersection of telehealth, compounding pharmacies and high‑demand GLP‑1 markets.